| Anthocyanins — Anthocyanins (ACNs) are a structurally diverse class of water-soluble flavonoid pigments (glycosylated anthocyanidins) abundant in berries, purple/red grapes, cherries, red cabbage, and other deeply colored plants. They function as pleiotropic redox- and inflammation-modulating polyphenols with context-dependent signaling effects that can shift from antioxidant/anti-inflammatory tone at nutritionally relevant exposures to stress-signaling/pro-apoptotic effects in tumor models at higher concentrations. Classification: dietary polyphenols (flavonoids; anthocyanidin O-glycosides). Standard abbreviations: ACNs; often specified as C3G (cyanidin-3-O-glucoside) or as “total anthocyanins.” A key translation nuance is that circulating parent ACNs are typically low and transient, while phase-II conjugates and gut microbiota–derived phenolic acids (e.g., protocatechuic acid from cyanidin glycosides) plausibly mediate a meaningful fraction of systemic biology.
Primary mechanisms (ranked):
- Inflammation attenuation via NF-κB pathway suppression and downstream cytokines/COX-2/iNOS modulation
- Growth/survival signaling downshift (PI3K–Akt–mTOR and intersecting MAPK nodes; context- and model-dependent)
- Redox modulation (biphasic): antioxidant tone and inflammatory redox dampening at low exposure; pro-oxidant stress signaling at high concentration in tumor models (secondary)
- Mitochondria-linked intrinsic apoptosis and cell-cycle checkpoint control (often downstream of NF-κB/Akt/redox)
- Anti-invasive/anti-metastatic remodeling (EMT programs, MMPs, adhesion/invasion)
- Anti-angiogenic signaling (VEGF axis; endothelial migration/tube formation)
- Metabolic reprogramming pressure (HIF-1α/glycolysis programs; secondary, model-dependent)
- Microbiome–host signaling (barrier function, metabolite signaling, bile acid/SCFA context; indirect systemic mechanism)
- NRF2 antioxidant response activation in normal tissues with mixed implications in NRF2-addicted tumors (secondary)
Bioavailability / PK relevance: Oral bioavailability of intact parent anthocyanins is generally modest with rapid appearance and clearance; extensive phase-II metabolism (glucuronidation/sulfation/methylation) and prominent gut microbiota catabolism generate phenolic acid metabolites that may dominate systemic exposure. Local gastrointestinal exposures can be substantially higher than plasma levels, making “GI-local” mechanisms more plausible than “systemic parent-compound” mechanisms for many endpoints.
In-vitro vs systemic exposure relevance: Many anticancer in-vitro studies use ~10–100+ µM parent anthocyanins/extract equivalents, which often exceed achievable circulating parent anthocyanin concentrations after dietary intake; therefore, mechanistic claims that require high micromolar parent exposure should be treated as (high concentration only) unless supported by metabolite biology or GI-local relevance.
Clinical evidence status: Human evidence is strongest for cardiometabolic and inflammation-related biomarkers (multiple RCTs/meta-analyses). For cancer, evidence is predominantly preclinical and epidemiologic/biomarker-level in humans; there is no established oncology indication or regulatory approval as an anticancer drug. For cognition/brain aging, small RCTs with anthocyanin-rich foods/supplements show signal in select domains, but overall evidence remains exploratory.
"Anthocyanins are a class of water‐soluble flavonoids, which show a range of pharmacological effects, such as prevention of cardiovascular disease, obesity control and antitumour activity. Their potential antitumour effects are reported to be based on a wide variety of biological activities including antioxidant; anti‐inflammation; anti‐mutagenesis; induction of differentiation; inhibiting proliferation by modulating signal transduction pathways, inducing cell cycle arrest and stimulating apoptosis or autophagy of cancer cells; anti‐invasion; anti‐metastasis; reversing drug resistance of cancer cells and increasing their sensitivity to chemotherapy."
Anthocyanins are flavonoid pigments with multi-target pleiotropic effects in cancer models, primarily through modulation of ROS balance, NF-κB signaling, PI3K/Akt/mTOR inhibition, apoptosis induction, and anti-angiogenic activity. Their effects are often context-dependent and dose-dependent: low physiologic exposures tend to support antioxidant and anti-inflammatory tone, whereas higher concentrations in vitro can induce oxidative stress and apoptosis in tumor cells. They also influence tumor microenvironment dynamics including VEGF signaling, MMP activity, and inflammatory cytokines. Bioavailability is modest, and metabolites (phenolic acids) likely contribute significantly to biological effects. Evidence in humans remains supportive but not definitive.
• Anthocyanins are a class of water-soluble flavonoid pigments responsible for the red, purple, and blue hues in many fruits, vegetables, and flowers (e.g., berries, red grapes, and eggplants).
• Anthocyanins can effectively scavenge free radicals and reduce oxidative stress, thereby protecting cellular components like DNA, lipids, and proteins from oxidative damage—a factor linked to carcinogenesis.
• Their antioxidant capacity helps in neutralizing reactive oxygen species (ROS), which can otherwise promote mutations and tumor initiation.
• Anthocyanins have been shown to inhibit pro-inflammatory cytokines (e.g., TNF-α, IL-6) and enzymes (e.g., COX-2), reducing the inflammatory signals associated with cancer progression.
• They may modulate pathways such as NF-κB, MAPK, and PI3K/Akt, contributing to the downregulation of genes involved in survival and proliferation of cancer cells.
• Anthocyanins have been found to inhibit the formation of new blood vessels (angiogenesis) essential for tumor growth and metastatic spread.
Black Rice and Comparable Anthocyanin-Rich Foods
The principal anthocyanins in black rice are cyanidin-3-glucoside (C3G) and peonidin-3-glucoside (P3G). Several berries, legumes, and pigmented grains contain similar compounds and may provide comparable or higher dietary anthocyanin exposure. Concentrations vary considerably by cultivar, growing conditions, processing, and analytical method.
| Rank |
Food |
C3G mg/100g |
P3G mg/100g |
Total Anthocyanins mg/100g |
Basis |
Notes / Interpretation |
| 1 |
Black Rice Bran |
926–2277 |
792–1422 |
1718–3699* |
Dry bran |
Extremely concentrated source. Total shown represents C3G + P3G only, not all anthocyanins. Not directly comparable to whole grain. |
| 2 |
Purple Corn / Purple Maize |
Major anthocyanin; variable |
Present; variable |
50–500 (typical comparison range) |
Dry kernels |
Rich in C3G, P3G, and pelargonidin derivatives. Published total anthocyanin values vary widely, including approximately 2–415 mg/100 g dry kernels. Highly pigmented samples may exceed 500 mg/100 g. Values generally expressed as C3G equivalents. Purple corn cobs can contain approximately 1,900–2,900 mg/100 g but are not directly comparable to edible kernels. |
| 3 |
Black Rice |
48–208 |
7–65 |
55–265* |
Dry whole grain |
Values from selected cultivars including Riceberry, Hom Nil, Artemide, Chakhao, and CMU 125. Total represents the combined C3G + P3G values for individual cultivars. |
| 4 |
Black Soybeans |
127 |
Not quantified in cited sample |
212 |
Study sample |
C3G constituted approximately 60% of measured anthocyanins. Also supplies soy isoflavones, protein, and dietary fiber. |
| 5 |
Blackberries |
88 |
Not significant |
95 |
Fresh fruit |
Excellent dietary C3G source. Can be consumed without cooking. Values from a comparative berry study. |
| 6 |
Black Mulberries |
Variable; C3G dominant |
Not a major constituent |
75–115 |
Fresh fruit |
Total anthocyanins expressed as C3G equivalents in one study. Cyanidin-3-rutinoside is also prominent. Fresh dark Morus nigra berries are preferable when anthocyanin intake is the goal. |
| 7 |
Aronia / Black Chokeberries |
Minor constituent |
Not a major constituent |
Up to 690 |
Fresh fruit |
Very high cyanidin-derived anthocyanins, predominantly cyanidin-3-galactoside and cyanidin-3-arabinoside rather than C3G. |
| 8 |
Elderberries |
Major constituent; variable |
Not a major constituent |
Up to 810 |
Fresh fruit |
Rich in cyanidin-3-glucoside and cyanidin-3-sambubioside. Must be properly processed before consumption. |
| 9 |
Bilberries / Wild European Blueberries |
Present; variable |
Minor constituent |
Up to 1000 |
Fresh fruit |
Very high total anthocyanins, with a broad profile containing cyanidin, delphinidin, malvidin, and other glycosides. |
| 10 |
Blackcurrants |
6.5 |
Not a major constituent |
114 |
Fresh fruit |
Representative comparative study. Delphinidin-3-rutinoside and cyanidin-3-rutinoside dominate. Other studies report substantially higher total anthocyanins. |
| 11 |
Blueberries (Cultivated) |
Minor to moderate; cultivar-dependent |
Present; variable |
80–300 |
Fresh fruit |
Typical commercial highbush blueberries. Approximately 150 mg/100 g is a reasonable representative value. Contains diverse anthocyanins, particularly malvidin, delphinidin, and petunidin glycosides. Wild blueberries may have higher concentrations. |
| 12 |
Purple Sweet Potatoes |
Variable |
Acylated peonidin derivatives prominent |
Highly cultivar-dependent |
Uncooked root |
Anthocyanins commonly occur as acylated cyanidin and peonidin derivatives rather than simple C3G/P3G. Cooking changes anthocyanin retention. |
Measurement notes: All quantities are mg per 100 g of the stated sample. Grain and bran values are based on dry material, while berry values generally represent fresh fruit. The asterisk indicates the sum of C3G and P3G, not independently measured total anthocyanins. Total anthocyanin values obtained by different analytical methods are not directly interchangeable, and maximum reported concentrations should not be interpreted as typical commercial values.
Clinical interpretation: Black rice, black soybeans, blackberries, and purple corn are particularly relevant when targeting dietary C3G exposure. Aronia, elderberries, bilberries, and blackcurrants can provide higher total anthocyanin concentrations but contain different anthocyanin profiles. Higher anthocyanin concentration does not establish superior bioavailability or clinical anticancer efficacy.
Practical recommendation: For frequent consumption, frozen blackberries provide C3G without cooking losses, while black rice and purple corn provide complementary anthocyanins in cereal-based foods. Black soybean offers additional protein and isoflavones but requires proper cooking. For concentrated supplementation, standardized extracts with independently verified anthocyanin content provide more reliable dose information than generic retail food labels.
Anthocyanins: ranked cancer-relevant pathway effects
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
NF-κB inflammatory transcription |
NF-κB ↓; IL-6/TNF-α/COX-2/iNOS ↓ (model-dependent) |
Inflammatory tone ↓; endothelial/immune activation ↓ (context-dependent) |
R, G |
Anti-inflammatory, anti-survival signaling pressure |
Often the most reproducible “systems-level” effect across anthocyanin mixtures; frequently upstream of apoptosis, invasion, and angiogenesis programs. |
| 2 |
PI3K–Akt–mTOR growth and survival |
Akt ↓; mTOR ↓; survival signaling ↓ (model-dependent) |
Metabolic stress signaling ↔/↓ (context-dependent) |
R, G |
Anti-proliferative signaling shift |
Commonly reported in breast/colon/liver/prostate models; “extract” studies can reflect multi-node inhibition rather than a single target. |
| 3 |
Mitochondria and intrinsic apoptosis |
MOMP ↑; caspases ↑; Bcl-2 family shift toward apoptosis (model-dependent) |
Pro-apoptotic signaling ↔/↓ at nutritional exposure; stress resistance ↑ (context-dependent) |
R, G |
Apoptosis induction / survival loss |
Frequently downstream of redox or Akt/NF-κB suppression; strong in vitro, but dose-exposure realism is the key constraint. |
| 4 |
ROS balance |
ROS ↑ (high concentration only) or ROS ↓ (context-dependent) |
ROS ↓; lipid peroxidation markers ↓ (often) |
P, R |
Redox buffering or stress signaling |
Biphasic: antioxidant/anti-inflammatory at low exposure; pro-oxidant stress signaling at higher concentrations in tumor models is reported but may be exposure-limited systemically. |
| 5 |
EMT and invasion programs |
EMT ↓; migration/invasion ↓ (model-dependent) |
Tissue remodeling ↔ (context-dependent) |
G |
Anti-invasive phenotype pressure |
Often linked to NF-κB, TGF-β/Smad, and MMP suppression; more consistent for “behavioral endpoints” than for a single molecular node. |
| 6 |
MMPs and extracellular matrix degradation |
MMP-2 ↓; MMP-9 ↓ (model-dependent) |
ECM turnover ↔ (context-dependent) |
G |
Reduced metastatic potential |
Pairs mechanistically with EMT suppression and inflammatory signaling downshift. |
| 7 |
Angiogenesis and VEGF axis |
VEGF signaling ↓; endothelial support ↓ (model-dependent) |
Endothelial activation ↓ (context-dependent) |
G |
Anti-angiogenic pressure |
Typically secondary to NF-κB/HIF-1α modulation; most convincing in models rather than as a clinically validated endpoint. |
| 8 |
Cell-cycle checkpoints |
G1/S or G2/M arrest ↑ (model-dependent) |
Cell-cycle stress ↔/↓ (context-dependent) |
R, G |
Proliferation restraint |
Often emerges as an integrated phenotype downstream of Akt/NF-κB redox signaling rather than a direct CDK inhibitor effect. |
| 9 |
HIF-1α and glycolysis programs |
HIF-1α ↓; glycolysis gene program ↓ (model-dependent) |
Metabolic flexibility ↔ (context-dependent) |
G |
Metabolic reprogramming pressure |
Best treated as secondary unless a specific anthocyanin/metabolite mechanism is shown at realistic exposure. |
| 10 |
NRF2 antioxidant response |
NRF2 ↔/↑/↓ (model-dependent) |
NRF2 ↑; cytoprotective enzymes ↑ (often) |
R, G |
Stress-response adaptation |
Potential benefit in normal-tissue protection; theoretical caution if a tumor is NRF2-addicted or relies on high antioxidant capacity. |
| 11 |
Ca²⁺ signaling |
Ca²⁺ flux ↔/disrupted (model-dependent) |
Excitotoxic stress signaling ↓ (context-dependent) |
P, R |
Signal modulation under stress |
Reported in subsets of models; generally not treated as a primary axis unless tied to a clear phenotype (e.g., apoptosis, barrier function). |
| 12 |
Clinical Translation Constraint |
Systemic parent exposure often low; heterogeneity of mixtures; biomarker-to-outcome gap |
Generally favorable food safety profile |
— |
Limits on “drug-like” claims |
Interpretation should weight GI-local effects, metabolite biology, and RCT biomarker outcomes higher than high-µM in-vitro parent-compound findings. |
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
Anthocyanins and Alzheimer’s disease — Anthocyanin-rich foods/supplements have small-human-trial signals suggesting modest improvements in selected cognitive domains and/or brain function proxies in at-risk or impaired cohorts, plausibly mediated through vascular/inflammatory tone, oxidative stress buffering, and microbiome–metabolite signaling (rather than sustained high circulating parent anthocyanins). Overall, evidence remains exploratory and heterogeneous across preparations, doses, and endpoints.
Clinical evidence status: Small RCTs/pilot trials (food-based and some purified preparations) with mixed but promising signals; not an established disease-modifying therapy.
Anthocyanins: non-cancer mechanisms relevant to Alzheimer’s disease
| Rank |
Pathway / Axis |
Modulation |
Primary Effect |
Notes / Interpretation |
| 1 |
Neuroinflammation |
↓ |
Lower inflammatory signaling tone |
Human biomarker/meta-analytic evidence supports anti-inflammatory effects in non-cancer contexts; translation to dementia outcomes remains unproven. |
| 2 |
Oxidative stress and redox homeostasis |
↓ |
Reduced oxidative burden; cytoprotection |
Mechanistically consistent with polyphenol biology; likely mediated substantially by metabolites rather than sustained parent anthocyanins. |
| 3 |
Neurovascular and endothelial function |
↑ |
Support for perfusion/vascular tone |
Common mechanistic bridge between cardiometabolic benefits and brain aging hypotheses; endpoints vary by trial design. |
| 4 |
Gut microbiota–metabolite axis |
↔ |
Metabolite signaling, barrier support |
Growing evidence that gut-derived phenolic acids contribute to systemic and possibly neuroactive effects; causal mapping in humans is still developing. |
| 5 |
Aβ processing and proteostasis |
↓ |
Potential reduction in amyloidogenic pressure |
Preclinical and mechanistic papers exist; human evidence for amyloid/tau modification is limited and not definitive. |
| 6 |
Clinical Translation Constraint |
— |
Heterogeneous preparations and endpoints |
Signals exist in small RCTs/pilots, but dose standardization, metabolite exposure mapping, and durable clinical outcomes remain the key gaps. |
|